NCT03743909

Brief Summary

  • To determine incidence of Expression of aberrant CD markers in acute leukemia in South Egypt .
  • Correlation between this expression and outcome of the patient.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2019

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 14, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 16, 2018

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

November 16, 2018

Status Verified

November 1, 2018

Enrollment Period

2 years

First QC Date

November 14, 2018

Last Update Submit

November 14, 2018

Conditions

Acute Leukemia

Outcome Measures

Primary Outcomes (1)

  • Expression of aberrant CD markers in acute leukemia by flowcytometry : Retrospective study in South Egypt Cancer Institute

    * To determine incidence of Expression of aberrant CD markers in acute leukemia in South Egypt . * Correlation between this expression and outcome of the patient.

    2008-2018

Study Arms (2)

patients with aberrant CD markers

by flowcytometry from hospital information system

patients without aberrant CD markers

by flowcytometry from hospital information system

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

acute leukemia patients

You may qualify if:

  • All cases of acute leukemia in South Egypt Cancer Institute.

You may not qualify if:

  • Cases outside South Egypt Cancer Institute.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

mervat A mohamed

CONTACT

01011893938mervatawad67@yahoo.com

douaa M sayed

CONTACT

01006261987douaa_sayed@hotmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
South Egypt cancer institute Assuit university

Study Record Dates

First Submitted

November 14, 2018

First Posted

November 16, 2018

Study Start

January 1, 2019

Primary Completion

January 1, 2021

Study Completion

April 1, 2021

Last Updated

November 16, 2018

Record last verified: 2018-11